A stress test by Crisil Ratings covering 34 sectors that account for 65% of its rated corporate debt suggests that India Inc remains broadl...

India’s future prosperity may increasingly depend on empowering its smaller economic units to become more productive using AI.

Indian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...

India's pharmaceutical sector, despite being the "pharmacy of the world," faces significant reliance on China for raw materials, with nearl...

Healthium Medtech's CEO Anish Bafna is transitioning to non-executive chairman as KKR-owned company seeks a new chief within a month. Bafna...

India's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...

Wright PMS's Sonam Srivastava champions a data-driven approach to active investing, analyzing over 300 data points to identify alpha. Her f...

When business updates start to come in or when some FMCG or auto companies indicate that things are not all good in the rural space, we may...

Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...

Corporate travel in India is increasingly shifting towards smaller cities, with nearly 60% of bookings now originating from or heading to t...

Aurobindo Pharma's US arm has secured Federal Trade Commission approval for its $250 million acquisition of Lannett Company. This strategic...

As the bulls attempt another serious comeback, the market again faces a familiar question: Are valuations still too high, or have they reac...

Global economic shocks from trade disruptions and geopolitical tensions are reshaping resilience, according to Raghuram Rajan. He stresses ...

Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

India's long-term growth outlook remains robust despite global geopolitical uncertainties and intermittent market volatility, supported by ...

Indian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...

Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...